⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9157488 | 0.74 | — | — | |
| SCHEMBL22824181 | 0.74 | — | — | |
| SCHEMBL30106458 | 0.74 | — | — | |
| SCHEMBL30491083 | 0.74 | — | — | |
| SCHEMBL30420491 | 0.74 | — | — | |
| SCHEMBL25292508 | 0.74 | — | — | |
| SCHEMBL1521909 | 0.74 | — | — | |
| SCHEMBL17987063 | 0.71 | S1PR4 (0.41) | — | |
| SCHEMBL1347449 | 0.70 | — | — | |
| SCHEMBL18910422 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743454-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS USP1 INHIBITORS | Laekna Pharmaceutical Ningbo Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20250171473-A1 | Phosphorous Containing BCL Inhibitors and Senolytic Compounds and Uses Thereof | Rubedo Life Sciences, Inc. | 2025-05-29 | — | — | US | disclosed |
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118591534-A | Novel benzimidazole pyridine derivatives | 豪夫迈·罗氏有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114585628-B | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117069724-A | Fused ring compounds, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| US-20220313698-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-06 | — | — | US | disclosed |
| EP-4013759-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114585628-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021030556-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030556-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-2404918-B1 | PYRIDINE DERIVATIVE AS PPARY INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8946264-B2 | Pyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130204009-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-08 | — | — | US | disclosed |
| EP-2615081-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-21 | — | — | US | disclosed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2404918-A1 | PYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-11 | — | — | EP | disclosed |